BRIEF published on 06/18/2026 at 13:57, 4 months 15 days ago ABL Diagnostics prévoit une croissance notable et un fort potentiel de développement. Partenariats Stratégiques Recommandation D'achat Augmentation Des Revenus Croissance 2026 Diagnostics ABL
BRIEF published on 06/18/2026 at 13:57, 4 months 15 days ago ABL Diagnostics: Growth and Outlook for 2026 INVEST SECURITIES Growth Partnerships Molecular Diagnosis Genotyping
BRIEF published on 06/18/2026 at 13:57, 4 months 15 days ago ABL Diagnostics Projects Notable Growth and Upward Potential Strategic Partnerships Revenue Increase Buy Recommendation ABL Diagnostics Growth 2026
BRIEF published on 06/18/2026 at 13:57, 4 months 15 days ago ABL Diagnostics : Croissance et Perspectives pour 2026 Croissance Partenariats INVEST SECURITIES Diagnostic Moléculaire Génotypage
PRESS RELEASE published on 06/18/2026 at 13:52, 4 months 15 days ago Inside Information / Other news releases ABL Diagnostics confirms growth trajectory with strong upside potential. Invest Securities raises target price to €8.7 and maintains 'Buy' recommendation INVEST SECURITIES Target Price Growth Trajectory Upside Potential ABL Diagnostics
PRESS RELEASE published on 06/18/2026 at 13:52, 4 months 15 days ago Informations privilégiées / Autres communiqués ABL Diagnostics confirme sa trajectoire de croissance avec un fort levier de revalorisation identifié. Recommandation d'achat avec objectif de cours à 8,7€ Croissance Recommandation D'achat Objectif De Cours Diagnostic Moléculaire ABL Diagnostics
BRIEF published on 06/12/2026 at 08:05, 4 months 22 days ago ABL Diagnostics and CDL Pharma sign a €2.7 million contract until 2031 Clinical Trials Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma
BRIEF published on 06/12/2026 at 08:05, 4 months 22 days ago ABL Diagnostics et CDL Pharma signent un contrat de 2,7 M€ jusqu'en 2031 Essais Cliniques Maladies Neurodégénératives ABL Diagnostics Contrat Pluriannuel CDL Pharma
BRIEF published on 06/12/2026 at 08:05, 4 months 22 days ago ABL Diagnostics et CDL Pharma décrochent un contrat de 2,7 millions d'euros Maladies Neurodégénératives Contrat International Programme Clinique Diagnostics ABL CDL Pharma
BRIEF published on 06/12/2026 at 08:05, 4 months 22 days ago ABL Diagnostics and CDL Pharma Secure €2.7 Million Contract Clinical Program Neurodegenerative Diseases International Contract ABL Diagnostics CDL Pharma
Published on 11/04/2026 at 00:05, 10 hours 35 minutes ago Scoping Study Begins for High-Grade Underground Mine Feed
Published on 11/04/2026 at 00:00, 10 hours 40 minutes ago RE Royalties Launches $5 Million Series 5 Green Bond Offering and Provides Strategic Growth Update
Published on 11/03/2026 at 23:30, 11 hours 10 minutes ago AT&T and Amdocs Expand Collaboration, Bringing Together Amdocs aOS and AT&T's AI-Enabled Framework to Simplify Operations and Improve Customer Experiences
Published on 11/03/2026 at 23:30, 11 hours 10 minutes ago GGL Resources Corp. Issues Post-Consolidation Shares to Strategic Metals Ltd.
Published on 11/04/2026 at 10:01, 38 minutes ago Komax Group aligns its organization to be consistently market-oriented
Published on 11/04/2026 at 09:15, 1 hour 24 minutes ago Fox ESS Signs Youngest Porsche Carrera Cup Germany Winner, Champion On and Off the Track
Published on 11/04/2026 at 09:15, 1 hour 24 minutes ago Omnissa expands Sovereign Solution to more markets, designed to give enterprises a safe place to run AI
Published on 11/04/2026 at 09:05, 1 hour 34 minutes ago New global Mouth-to-Body Health Institute aims to turn oral-systemic science into better prevention and care
Published on 11/04/2026 at 09:00, 1 hour 39 minutes ago Original-Research: GFT Technologies SE (von NuWays AG): BUY
Published on 11/04/2026 at 09:21, 1 hour 18 minutes ago Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Published on 11/03/2026 at 18:39, 16 hours 1 minute ago NRJ Group - Information relative aux droits de vote au 31.10.2026 (French & English)
Published on 11/03/2026 at 18:00, 16 hours 40 minutes ago Outstanding Shares and Voting Rights Monthly Statement - 31 October 2026
Published on 11/03/2026 at 18:00, 16 hours 40 minutes ago Publication mensuelle du nombre d’actions composant le capital et du nombre total de droits de vote - 31 octobre 2026
Published on 11/03/2026 at 17:45, 16 hours 55 minutes ago Declaration of voting rights at the end of October 2026
